Corebridge Financial Inc. Sells 897 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Corebridge Financial Inc. cut its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 7.0% during the 4th quarter, Holdings Channel reports. The firm owned 11,883 shares of the company’s stock after selling 897 shares during the period. Corebridge Financial Inc.’s holdings in Dianthus Therapeutics were worth $259,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC increased its position in shares of Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after buying an additional 814 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Dianthus Therapeutics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock worth $3,641,000 after buying an additional 1,092 shares during the period. R Squared Ltd bought a new position in shares of Dianthus Therapeutics in the 4th quarter worth about $26,000. Rhumbline Advisers boosted its stake in Dianthus Therapeutics by 3.8% during the fourth quarter. Rhumbline Advisers now owns 35,933 shares of the company’s stock worth $783,000 after acquiring an additional 1,316 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $33,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DNTH has been the subject of several analyst reports. Guggenheim restated a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $54.33.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $17.61 on Friday. The firm has a market capitalization of $565.72 million, a PE ratio of -7.04 and a beta of 1.62. The stock has a fifty day simple moving average of $20.67 and a two-hundred day simple moving average of $23.38. Dianthus Therapeutics, Inc. has a 52-week low of $13.37 and a 52-week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.